401 Epizód

  1. Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community

    Közzétéve: 2021. 05. 28.

  2. Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer

    Közzétéve: 2021. 05. 26.

  3. Episode 100: The Uromigos 100th Podcast - Looking to the Future

    Közzétéve: 2021. 05. 21.

  4. Episode 99: Navigating social media from a patients' perspective

    Közzétéve: 2021. 05. 19.

  5. Episode 98: Bladder cancer from a patient perspective

    Közzétéve: 2021. 05. 19.

  6. Episode 97: Sacituzumab Govitecan in Bladder Cancer

    Közzétéve: 2021. 05. 04.

  7. Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo

    Közzétéve: 2021. 04. 28.

  8. Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia

    Közzétéve: 2021. 04. 28.

  9. Episode 94: EIKCS Summary of Day 1

    Közzétéve: 2021. 04. 23.

  10. Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer

    Közzétéve: 2021. 04. 14.

  11. Episode 92: Second line therapy in advanced RCC

    Közzétéve: 2021. 04. 09.

  12. Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer

    Közzétéve: 2021. 03. 26.

  13. Episode 90: The Uromigos Podcast with QOL Expert David Cella

    Közzétéve: 2021. 03. 12.

  14. Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer

    Közzétéve: 2021. 03. 04.

  15. Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler

    Közzétéve: 2021. 02. 26.

  16. Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal

    Közzétéve: 2021. 02. 26.

  17. Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein

    Közzétéve: 2021. 02. 26.

  18. Episode 85: The CLEAR Trial

    Közzétéve: 2021. 02. 14.

  19. Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney

    Közzétéve: 2021. 02. 13.

  20. Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?

    Közzétéve: 2021. 02. 13.

16 / 21

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Visit the podcast's native language site